{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:58:25Z","timestamp":1789160305989,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.hoc.2025.04.018","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:30:54Z","timestamp":1761766254000},"page":"1077-1086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgery for Recurrent Ovarian Cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Evan J.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2025.04.018_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J Clin"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.018_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","article-title":"Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach","volume":"4","author":"Dood","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl 8","key":"10.1016\/j.hoc.2025.04.018_bib3","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.018_bib4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.04.018_bib5","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"National Cancer Institute monograph"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.018_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"3 Pt 1","key":"10.1016\/j.hoc.2025.04.018_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/gyno.2000.5926","article-title":"A critique of surgical cytoreduction in advanced ovarian cancer","volume":"78","author":"Covens","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.018_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.018_bib10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.018_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib12","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"Berek","year":"1983","journal-title":"Obstet Gynecol"},{"issue":"15","key":"10.1016\/j.hoc.2025.04.018_bib13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.018_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13048-021-00842-9","article-title":"The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Ding","year":"2021","journal-title":"J Ovarian Res"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.018_bib15","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.018_bib16","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2025.04.018_bib17","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2015.02.004","article-title":"External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer","volume":"137","author":"van de Laar","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0000000000000051","article-title":"Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system","volume":"24","author":"Laas","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.hoc.2025.04.018_bib23","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.018_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.018_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2025.04.018_bib26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2025.04.018_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133470","article-title":"Surgery in Recurrent Ovarian Cancer: A Meta-Analysis","volume":"15","author":"Climent","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.018_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2025.04.018_bib29","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2016.09.002","article-title":"Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States","volume":"143","author":"Melamed","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2025.04.018_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2023.01.017","article-title":"Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy","volume":"172","author":"Jorgensen","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2017.05.022","article-title":"Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes","volume":"146","author":"Eriksson","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.018_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ygyno.2014.05.007","article-title":"Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study","volume":"134","author":"Escobar","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.018_bib34","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3802\/jgo.2022.33.e63","article-title":"Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study","volume":"33","author":"Shi","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.018_bib35","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jog.15673","article-title":"A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer","volume":"49","author":"Yang","year":"2023","journal-title":"J Obstet Gynaecol Res"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.018_bib36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:02:29Z","timestamp":1761840149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889858825000565"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.018","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery for Recurrent Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}